(Press-News.org) Despite the importance of site investigators to the success of multicentre clinical trials, inadequate public information is available about their recruitment performance. In this week's PLoS Medicine, Rafael Dal-Ré and colleagues argue that that sponsors should disclose the recruitment targets of all site investigators on ClinicalTrials.gov before a trial starts, as well as their final recruitment. Information on issues that could have affected recruitment should also be provided. This information will be of interest to different stakeholders such as patient organizations, sponsors, and MCT networks, say the authors.
The authors state that: "Disclosing all site investigators' recruitment figures could prompt queries to the sponsor from the scientific community about regional subgroup analyses, to be able to assess if ethnic or standard-of-care differences have an impact on treatment outcomes."
###Funding: The authors received no specific funding for this article. Dr. D Moher is funded, in part, by a University Research Chair (University of Ottawa, Canada).
Competing Interests: RDR reports being a GlaxoSmithKline employee (as Medical Director in Spain) until 2009 and owning stock in this firm. XC is the chairperson of the Spanish Commmittee of Drug Evaluation, an external advisory board to the Spanish Medicines Agency (AEMPS). DM is a member of the PLoS Medicine Editorial Board. The ideas and opinions expressed here are those of the authors and do not necessarily reflect those of the institutions or organizations they work for. All other authors reported having no competing interests.
Citation: Dal-Ré R, Moher D, Gluud C, Treweek S, Demotes-Mainard J, et al. (2011) Disclosure of Investigators' Recruitment Performance in Multicenter Clinical Trials: A Further Step for Research Transparency. PLoS Med 8(12): e1001149. doi:10.1371/journal.pmed.1001149
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001149
PRESS-ONLY PREVIEW OF THE ARTICLE: www.plos.org/media/press/2011/plme-08-12-dal-re.pdf
CONTACT:
Rafael Dal-Ré
Early Detection Research Program
Alzheimer's Disease
Pasqual Maragall Foundation
Barcelona
Spain
+34649410221
rfdalre@gmail.com; rdal-re@fpmaragall.org
More information on trial site investigators needed
2011-12-29
ELSE PRESS RELEASES FROM THIS DATE:
Another potential obstacle to developing an HIV vaccine
2011-12-29
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]). A team of researchers led by Juliana McElrath, at the Fred Hutchinson Cancer Research Center, Seattle, has now determined that individuals from the STEP study ...
Does LASIK Hurt?
2011-12-29
Millions of people have undergone LASIK surgery throughout the world. As the most popular form of laser vision correction, it has been closely monitored by the FDA and several industry groups. In a recent analysis of over 60 studies worldwide, it was found that 95.4 percent of people who have received LASIK are very satisfied with their results. This same analysis found that LASIK was effective in providing vision of 20/20 or better in an overwhelming majority of instances. This is great news for people who long to live a life free of glasses, but it fails to address one ...
How obesity alters the brain area involved in body weight control
2011-12-29
The number of people who suffer from one or more of the adverse complications of obesity, including type 2 diabetes and heart disease is rapidly increasing. Thus far, drugs designed to treat obesity have shown limited efficacy and have been associated with serious side effects. This is largely because we have limited understanding of the effects of obesity on our natural mechanisms of body weight control. For example, while great strides have been made in our understanding of how the brain controls our desire to feed, as well as the processes underlying the balancing of ...
Beneficial or not beneficial: that is the question for IL-1 inhibition in atherosclerosis
2011-12-29
Atherosclerosis is a disease of the major arterial blood vessels. It is one of the major causes of heart attack and stroke. The proinflammatory molecule IL-1 has been linked to atherosclerosis and a clinical trial has been launched in which an antibody specific for IL-1-beta is being studied for its effects on the severe clinical complications of atherosclerosis (i.e., heart attack and stroke). However, a team of researchers led by Gary Owens, at the University of Virginia, Charlottesville, has now generated data in mice that raise potential concerns about this clinical ...
JCI online early table of contents: Dec. 27, 2011
2011-12-29
EDITOR'S PICK
Another potential obstacle to developing an HIV vaccine
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]). A team of researchers led by Juliana McElrath, at the Fred Hutchinson Cancer Research ...
Tests for biomarker may help determine diagnosis of heart attack within hours
2011-12-29
CHICAGO – For patients admitted to an emergency department with chest pain, use of a contemporary or highly sensitive test for levels of troponin I (a protein in muscle tissue) may help rule-out a diagnosis of heart attack, while changes in the measured levels of this biomarker at 3 hours after admission may be useful to confirm a diagnosis of heart attack, according to a study in the December 28 issue of JAMA.
One of the most common reasons patients seek care in an emergency department is for acute chest pain. "Early identification of individuals at high and intermediate ...
Perception of inappropriate care frequent among ICU workers
2011-12-29
CHICAGO – A survey of nurses and physicians in intensive care units (ICUs) in Europe and Israel indicated that the perception of inappropriate care, such as excess intensity of care for a patient, was common, and that these perceptions were associated with inadequate decision sharing, communication and job autonomy, according to a study in the December 28 issue of JAMA.
"Clinicians perceive the care they provide as inappropriate when they feel that it clashes with their personal beliefs and/or professional knowledge. Intensive care unit workers who provide care perceived ...
Analysis does not support genetic test before use of anti-clotting drug
2011-12-29
CHICAGO – Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may be less responsive to the medication, a review and analysis of previous studies did not find an overall significant association between the CYP2C19 genotype and cardiovascular events, according to a study in the December 28 issue of JAMA.
Clopidogrel is an antiplatelet drug used by approximately 40 million patients worldwide to treat or prevent ...
Possible Defenses To A DUI Charge
2011-12-29
You are sitting in your car, watching the red lights in your rearview mirror. The officer exits their vehicle and begins walking toward your car.
The next thing you know, you have been charged with a DUI. What do you do now?
You may think you have no chance, that even though you did not feel intoxicated or impaired, the blood alcohol content reading of the breathalyzer showed you were over the limit, and you are as good as convicted. Machines don't make mistakes, do they?
Challenging A DWI Charge
While it may seem an open and shut case, there may be multiple ...
Oxidative DNA damage repair
2011-12-29
Oxidative stress is the cause of many serious diseases such as cancer, Alzheimer's, arteriosclerosis and diabetes. It occurs when the body is exposed to excessive amounts of electrically charged, aggressive oxygen compounds. These are normally produced during breathing and other metabolic processes, but also in the case of ongoing stress, exposure to UV light or X-rays. If the oxidative stress is too high, it overwhelms the body's natural defences. The aggressive oxygen compounds destroy genetic material, resulting in what are referred to as harmful 8-oxo-guanine base mutations ...